Novo Signs $812 Million Weight-Loss Drug License Deal with Deep Apple

Reported 1 day ago

Novo Nordisk has entered a partnership with Deep Apple Therapeutics to develop new drugs for cardiometabolic diseases, including obesity, in a deal potentially worth up to $812 million. This agreement grants Novo exclusive rights to develop non-incretin oral therapies, expanding its influence in the weight-loss drug market as it faces increasing competition.

You may also interested in these wikis

Google Offers Buyouts to U.S. Employees Amid Workforce Reductions

The Financial Challenges of Sponsoring Major LGBTQ Events

Wedbush Analysts Highlight Oklo as a Leader in Nuclear Energy Growth

Protests Erupt in New York and Chicago Following LA Curfew

Companies Create Tools to Assist Shippers with Tariff Costs

Chloé Daniels' Tips for Early Retirement Without Sacrifices

Decreasing Investor Activity May Benefit Homebuyers

May Inflation Stays at 2.4%, Defying Tariff Concerns

Analyst Report: Centerpoint Energy Inc.

Daily Spotlight: Bond Spreads Tick Wider

Back to all Wikis